神经甾体在精神科精准医学中的潜力
本文综述生物标志物开发与精神科个体化医疗现状,指出神经甾体治疗对产后抑郁有效但未获批准用于重性抑郁障碍,可能因缺乏患者分层。新兴研究表明内源性神经甾体合成能力改变的生物标志物有助于识别产后抑郁风险个体并预测治疗反应。
要点
- 神经甾体治疗对产后抑郁有效,但对重性抑郁障碍未获批准,可能因未能分层。
- 内源性神经甾体合成能力改变的生物标志物或可识别产后抑郁风险并预测治疗反应。
- 生物标志物方法可能具有跨诊断潜力,用于精神疾病诊断与治疗。
核心结论
- 神经甾体治疗对产后抑郁有效但未获批准用于重性抑郁障碍,可能因缺乏患者分层。
- 内源性神经甾体合成能力改变的生物标志物或有助于识别产后抑郁风险个体并预测神经甾体治疗反应。
研究设计与样本
- 本文为综述,总结生物标志物开发与精神科个体化医疗现状。
- 综述涵盖内源性神经甾体脑内产生、神经甾体治疗临床现状及神经甾体合成能力作为生物标志物的潜在用途。
主要发现
- 神经甾体治疗对产后抑郁有效。
- 神经甾体治疗未获批准用于重性抑郁障碍,可能因无法分层适宜患者。
- 新兴研究表明内源性神经甾体合成能力改变或降低的生物标志物有助于识别产后抑郁风险个体。
临床怎么用
- 可考虑测量内源性神经甾体合成能力作为生物标志物,用于识别产后抑郁风险个体并预测神经甾体治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
One of the most significant challenges in treating individuals with psychiatric illnesses is the biological heterogeneity that exists throughout the patient population. This heterogeneity has hindered both timely diagnoses for those impacted as well as the development of new treatment options to combat these disorders. Ongoing efforts have been centered around stratifying individuals based on comprehensive phenotyping; however, biological heterogeneity remains a critical driver of psychiatric illness and poses a significant challenge in the field. Here, we review the current state of the field in biomarker development and the need for personalized medicine in psychiatry. Neurosteroid-based treatments have proven effective for the treatment of postpartum depression but failed to gain approval for major depressive disorder, likely due to the inability to stratify patients amenable to this treatment approach. We discuss the potential of a biomarker approach to identify individuals with disruption in endogenous neurosteroid synthesis that may have transdiagnostic potential. Exciting emerging studies suggest that a biomarker indicating altered or reduced capacity for endogenous neurosteroidogenesis would be beneficial for identifying individuals at risk for postpartum depression and could potentially predict treatment response to neurosteroid-based treatments. This review aims to provide a comprehensive report on the production of endogenous neurosteroids in the brain, the current clinical landscape for the use of neurosteroid-based therapies in psychiatry, and the potential utility of measuring neurosteroidogenesis capacity as a biomarker for the diagnosis and treatment of psychiatric illnesses.
引用
- Dargan TL, Walton NL, Maguire JL, et al. Potential of Neurosteroids for Precision Medicine in Psychiatry. Biol Psychiatry. 2026. PMID: 42480802. doi:10.1016/j.biopsych.2026.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。